Researchers Attempting to Speed Up Vaccine Making Process

Share this content:
While the team is now testing their version of the cell-free, recombinant DNA process for vaccine production, they’ve already successfully demonstrated it for at least one anti-cancer protein.
While the team is now testing their version of the cell-free, recombinant DNA process for vaccine production, they’ve already successfully demonstrated it for at least one anti-cancer protein.

Researchers at Brigham Young University are developing a system to speed up the process of making vaccines for new viruses.

The concept is to create the biological machinery for vaccine production en masse, put it in a freeze-dried state and stockpile it. Then, when a new virus hits, labs can simply add water to a “kit” to rapidly produce vaccines.

“You could just pull it off the shelf and make it,” senior author Brad Bundy, associate professor of chemical engineering said in a press release about the system. “We could make the vaccine and be ready for distribution in a day.”

The research, published in Biotechnology Journal, demonstrates the ability to store the drug and vaccine-making machinery for more than a year.

Traditional systems to produce vaccines for pandemic influenza strains require heavy engineering and specialized equipment that only a few labs across the country have on hand. These traditional systems are also time-consuming, taking months to execute.

This idea is a new angle on the emerging method of “cell-free protein synthesis,” a process that combines DNA to make proteins needed for medications. The lab is creating a system where the majority of the work is done beforehand so vaccine kits can be ready to go when needed.

While the team is now testing their version of the cell-free, recombinant DNA process for vaccine production, they've already successfully demonstrated it for at least one anti-cancer protein.

The researchers said in the statement they believe their method can significantly reduce investment of time and money toward future drug production and, in turn, reduce treatment expenses for patients.

“The drugs today are changing,” Dr Bundy said. “The lifesaving cancer drugs we have now, the drugs for arthritis, the drugs with the greatest impact, are made out of proteins, not small chemical molecules. This method takes full advantage of that to provide a quicker, more personal response.”

Reference

  1. Salehi AS, Smith MT, Bennett AM et al. Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.Biotech J. 2015;DOI: 10.1002/biot.201500237.
You must be a registered member of Infectious Disease Advisor to post a comment.

Sign Up for Free e-newsletters